Alkermes Plc (ALKS) Stock Price, Quote & News

Latest News on ALKS

Apr 17, 2025, 4:00 PM EDT - 4 days ago

Alkermes to Report First Quarter Financial Results on May 1, 2025

Apr 2, 2025, 4:00 PM EDT - 19 days ago

Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 20 days ago

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

Mar 27, 2025, 7:00 AM EDT - 25 days ago

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

Feb 26, 2025, 4:00 PM EST - 7 weeks ago

Alkermes to Participate in Upcoming Investor Conferences

Feb 25, 2025, 5:08 AM EST - 7 weeks ago

Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment

Feb 12, 2025, 2:40 PM EST - 2 months ago

Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 2 months ago

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

Feb 5, 2025, 4:00 PM EST - 2 months ago

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

Jan 2, 2025, 4:00 PM EST - 3 months ago

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 24, 2024, 9:58 AM EST - 5 months ago

Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth

Nov 11, 2024, 4:00 PM EST - 5 months ago

Alkermes to Participate in Two Upcoming Investor Conferences

Nov 7, 2024, 7:00 AM EST - 5 months ago

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

Oct 24, 2024, 1:04 PM EDT - 6 months ago

Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 7:00 AM EDT - 6 months ago

Alkermes plc Reports Third Quarter 2024 Financial Results

Oct 17, 2024, 4:00 PM EDT - 6 months ago

Alkermes to Report Third Quarter Financial Results on October 24, 2024

Sep 25, 2024, 8:00 AM EDT - 7 months ago

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

Sep 23, 2024, 7:00 AM EDT - 7 months ago

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

Sep 13, 2024, 7:00 AM EDT - 7 months ago

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

Aug 28, 2024, 4:00 PM EDT - 8 months ago

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 7:00 AM EDT - 8 months ago

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

Jul 24, 2024, 2:20 PM EDT - 9 months ago

Alkermes plc (ALKS) Q2 2024 Earnings Call Transcript

Jul 24, 2024, 7:00 AM EDT - 9 months ago

Alkermes plc Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 4:00 PM EDT - 9 months ago

Alkermes to Report Second Quarter Financial Results on July 24, 2024

Jun 3, 2024, 7:00 AM EDT - 11 months ago

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

May 28, 2024, 7:00 AM EDT - 11 months ago

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

May 17, 2024, 8:27 AM EDT - 1 year ago

The Bottom Fishing Club: Alkermes Has Great Value And Safety

May 14, 2024, 7:00 AM EDT - 1 year ago

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

May 2, 2024, 7:00 AM EDT - 1 year ago

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

May 1, 2024, 7:00 AM EDT - 1 year ago

Alkermes plc Reports First Quarter 2024 Financial Results

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

Apr 17, 2024, 4:00 PM EDT - 1 year ago

Alkermes to Report First Quarter Financial Results on May 1, 2024

Apr 9, 2024, 4:29 PM EDT - 1 year ago

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Apr 9, 2024, 9:49 AM EDT - 1 year ago

Alkermes plc: Collecting The Fruits Of The 2023 Spinoff

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

Mar 7, 2024, 7:00 AM EST - 1 year ago

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Feb 15, 2024, 3:08 PM EST - 1 year ago

Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 7:00 AM EST - 1 year ago

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024

Feb 8, 2024, 4:00 PM EST - 1 year ago

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024

Jan 26, 2024, 3:33 PM EST - 1 year ago

Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage

Jan 3, 2024, 4:00 PM EST - 1 year ago

Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)

Dec 14, 2023, 6:05 AM EST - 1 year ago

Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk

Nov 15, 2023, 7:00 AM EST - 1 year ago

Alkermes Completes Separation of Oncology Business

Nov 10, 2023, 2:46 PM EST - 1 year ago

Alkermes plc: A Spread Trade On The Spin-Off To Capture Valuations Re-Rate

Nov 7, 2023, 4:00 PM EST - 1 year ago

Alkermes to Participate in the Jefferies London Healthcare Conference

Oct 31, 2023, 5:08 PM EDT - 1 year ago

Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement

Oct 25, 2023, 4:28 PM EDT - 1 year ago

Alkermes plc (ALKS) Q3 2023 Earnings Call Transcript

Oct 25, 2023, 7:00 AM EDT - 1 year ago

Market Cap	4.45B
Revenue (ttm)	1.56B
Net Income (ttm)	367.07M
EPS (ttm)	N/A
PE Ratio	11.24
Forward PE	21.02
Profit Margin	23.57%
Debt to Equity Ratio	0.00

Volume	1,855,632
Avg Vol	1,922,608
Day's Range	N/A - N/A
Shares Out	164.84M
Stochastic %K	30%
Beta	0.39
Analysts	Strong Sell
Price Target	$39.13